Researchers at UVA developed an AI imaging tool using PET/MR to distinguish treatment effects from tumor progression in glioblastoma patients.
Key Details
- 1AI tool analyzes PET/MR imaging findings in glioblastoma cases.
- 2Distinguishes between tissue changes due to treatment vs. tumor progression.
- 3Current monitoring approaches often require a waiting period of 3+ months.
- 4Faster distinction could enable earlier treatment modification for recurrence.
- 5Method developed by a University of Virginia team.
Why It Matters
Improved differentiation between treatment effects and recurrence could allow clinicians to adjust therapies more quickly, potentially improving outcomes for a highly aggressive brain cancer. This underlines the growing significance of AI-assisted multi-modal imaging in oncology workflows.
Source
Health Imaging
Related News
•Radiology Business
Lucida Medical Raises $11M for AI-Based Prostate MRI Diagnosis Expansion
Lucida Medical, specializing in AI-assisted prostate cancer diagnosis via MRI, raises $11.4M to drive US FDA approval and platform expansion.
•Radiology Business
AI Guidance Cuts Novice Ultrasound Exam Time by 34%
AI guidance significantly reduces exam times and enhances diagnostic quality for novice ultrasound operators performing shoulder exams.
•AuntMinnie
AI Models Reveal Racial Disparities in Breast Cancer Patterns
Machine learning models reveal significant racial disparities and key predictors in breast cancer incidence across diverse groups.